To redirect T cells against tumor cells, T cells can be engineered ex vivo to express cancer-
antigen specific T cell receptors (TCRs), generating products known as TCR-engineered T …

Harnessing the immune system to recognize and destroy tumor cells has been the central
goal of anti-cancer immunotherapy. In recent years, there has been an increased interest in …

Adoptive transfer of T lymphocytes is a promising treatment for a variety of malignancies but
often not feasible due to difficulties generating T cells that are reactive with the targeted …

Relapse remains a leading cause of death after allogeneic hematopoietic cell
transplantation (HCT) for patients with high-risk leukemias. The potentially beneficial donor …

Abstract Purpose: Listeria monocytogenes (Lm)-based vaccines stimulate both innate and
adaptive immunity. ANZ-100 is a live-attenuated Lm strain (Lm Δ actA/Δ inlB). Uptake by …

We present an overview of clinical trials involving gene editing using clustered interspaced
short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9), transcription …

CD137 is a member of the TNFR-family with costimulatory function. Here we show that it
also has many favorable characteristics as a surrogate marker for antigen-specific activation …

Deregulation of signaling pathways is a hallmark of malignant transformation. Signaling-
associated phosphoproteins can be degraded to generate cancer-specific phosphopeptides …

Over the past decades, adoptive transfer of T cells has revolutionized cancer
immunotherapy. In particular, T-cell receptor (TCR) engineering of T cells has marked …

Human cytomegalovirus (CMV) infections and relapse of disease remain major problems
after allogeneic stem cell transplantation (allo-SCT), in particular in combination with CMV …